

mucin1. In one preferred embodiment, the polypeptide binding to mucin1 of the present disclosure may be an antibody or an antigen-binding fragment thereof.

In one embodiment, provided is a polypeptide binding to mucin1, the polypeptide comprising a pair of a heavy chain variable (VH) region and a light chain variable (VL) region selected from the following VH and VL regions:

- a VH region comprising complementarity-determining region(CDR) 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, and a VL region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6, respectively;

- a VH region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 13, respectively, and a VL region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16, respectively;

- a VH region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 21, SEQ ID NO: 22, and SEQ ID NO: 23, respectively, and a VL region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively;

- a VH region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 31, SEQ ID NO: 32, and SEQ ID NO: 33, respectively, and a VL region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 34, SEQ ID NO: 35, and SEQ ID NO: 36, respectively;

- a VH region comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 41, SEQ ID NO: 42, and SEQ ID NO: 43, respectively, and a VL region

comprising CDR 1, 2, and 3 represented by amino acid sequences of SEQ ID NO: 44, SEQ ID NO: 45, and SEQ ID NO: 46, respectively;

- a VH region comprising CDR 1, 2, and 3 represented by amino acid sequences of